Pfizer Lyrica lost 57% market share in three weeks after being blocked by nine generic drugs!

Recently, the bionics of Avastin and Herceptin, the Rogowski blockbuster, landed in the United States and was listed as the top drugs in the catalogue by unh health insurance (for details, unh listed two bionics as the top drugs in the catalogue) Lyrica, Pfizer's star product, is also in a generic dilemma Lyrica is an antiepileptic and analgesic drug, which has been approved by more than 130 countries and regions in the world for various indications In 2018, Lyrica's sales in the United States reached $3.6 billion In late July, the US FDA approved Lyrica's first generic drugs (9 in total) The first batch of generic drugs came from nine pharmaceutical companies, including alembic, alkem laboratories, amneal, Dr Reddy's laboratories, invagen, MSN laboratories, rising pharmaceuticals, sciegen and TIWA (see: Pfizer Lyrica cool! Nine generic drugs were approved at the same time Although Pfizer has made the expectation that the sales of lycrica will decline after the generic drug goes on the market, at present, the reality seems to be worse than expected As of August 9, lycrica's prescription volume in the U.S market fell by nearly 57% due to the sharp impact of generic drug listing Lyrica lost 35% of its market share in the last week of July, according to iqvia data cited by SVB leerink Among the challengers Lyrica is facing, Novartis Sandoz occupies 9.7% of the market share, Cipla ranks second with 8.1% of the market share, followed by amneal and TIWA with 6.9% and 6.8% of the market share, respectively In the United States, Lyrica's patent originally expired on December 30, 2018 Due to the development of the pediatric epilepsy project, it obtained an additional six months of market monopoly period Compared with biological generic drugs, the impact of chemical generic drugs on brand drugs is catastrophic Once the chemical generic drugs enter the market, the brand drug sales will show a precipitous decline, and the sales will easily lose at least 50% in the first year With this in mind, global data expects sales of lycrica to fall rapidly after generic drugs go on the market, with an estimated $950 million in 2024 Fortunately, Pfizer is actively taking other measures to make up for the loss of profits caused by the decline in sales At present, Pfizer has not only transferred the hot potato to others, but also made a profit from small and medium-sized enterprises On July 29, Pfizer announced the complete divestiture of Upjohn, the non patent drug business, and the merger with Meilan, the generic giant After the merger of the two companies, the new company expects annual sales to exceed $20 billion The deal could change the competitive landscape of the global generic and generic markets Pfizer said the $12 billion the deal could bring would be used to pay off debt and return dividends to shareholders, and could also be used to supplement its existing business, which is not yet well developed After the split, Pfizer will transfer Lyrica and another popular drug Lipitor, which has been devalued for a long time after the US patent cliff, to mylan (see details: Pfizer and McLaren form the world's largest generic pharmaceutical company) it is worth noting that Pfizer will not face the expiration of the next drug patent until 2026 However, it is undeniable that the sales volume of Lyrica will continue to decrease in the future, but what is the lowest value? It may be judged by other drugs that suffer patent losses Lipitor lost patent protection and 90% of the U.S hypertension market share in 2011 However, due to the large size of the overall market, the brand still generated $408 million in revenue in the second quarter Viagra, another drug of Pfizer, has lost patent protection since the end of 2017 At present, the market share of the drug is barely maintained, but the sales volume has declined significantly Compared with the same period in 2016, the sales volume of the drug in the United States in the second quarter of 2019 dropped from $300 million to $114 million, down more than half Reference source: Lyrica looking grid: Pfizer blockbuster's market share faults under generic attack